Sirnaomics' Peptide Business Explodes! Raw Material Exports Increase by 97.51% in the First Half, Leading the Way in a $20 Billion Blue Ocean Market

Sirnaomics, a company that has been deeply involved in the peptide field for over 20 years, achieved significant growth in the export of peptide APIs in the first half of the year, with a year-on-year growth rate of 97.51%, showing its strong development momentum. Although the company experienced violent fluctuations in the capital market, its profound accumulation in the peptide field and stable performance growth have made it an important force in the industry.

Sirnaomics' three core businesses - innovative drug CDMO services for peptides, peptide formulations business, and peptide API business - have collectively driven growth in performance. Of these, the API business has performed particularly well, with overseas sales growing by 97.51% year-on-year, becoming one of the main driving forces for profit growth.

Peptide drugs are a type of emerging drugs that lie between small molecule chemical drugs and protein drugs, with advantages such as high activity, low toxicity, and quality control. They are suitable for solving complex diseases that are difficult to address with small molecule chemical drugs.

The global peptide drug market size has already exceeded $20 billion, accounting for about 2% of the total pharmaceutical market, but it has maintained a high growth rate of around 10%. Some of the most popular peptide drugs include GLP-1 analogues, used to treat type 2 diabetes, such as liraglutide and exenatide, with sales exceeding $3 billion. Growth hormone and growth hormone-like substances are used to treat diseases caused by disorders in growth hormone secretion, with global sales of approximately $2.8 billion and $2.4 billion, respectively. LHRH agonist analogs are used to treat prostate cancer, postmenopausal breast cancer, etc., with global sales of approximately $4.8 billion. Other popular peptide drugs include teriparatide and linagliptin. In the Chinese market, sales of peptide drugs are also growing rapidly. They reached RMB 63.05 billion in 2017, mainly due to the large population base, accelerating aging, and a large number of cancer and chronic disease patients. The market demand for this will continue to expand, and there is still significant growth potential for peptide drugs. The peptide drug market is currently in a period of rapid development, and is expected to exceed $6 billion in the next 10 years. As synthetic technology advances and new indications are developed, peptide drugs will play an increasingly important role in the treatment of cancer, diabetes, and rare diseases.

In recent years, as the peptide drug market has continued to expand, demand for upstream raw materials has soared. Sirnaomics has accumulated years of experience in synthesis and modification technologies, and has mastered several core technologies, solving technical bottlenecks for the production of multiple peptide raw materials. Currently, its API products have been sold to countries and regions such as Europe, the United States, and South Korea, and it has established cooperative relationships with many well-known pharmaceutical enterprises at home and abroad.

In the future, Sirnaomics will continue to increase its R&D investment, enhance its peptide drug R&D capabilities and optimize production processes. It will also accelerate the implementation progress of its ongoing construction projects to seize market development opportunities. As its future capacity gradually releases, Sirnaomics is expected to drive sustained growth in its performance.